Medicare GLP-1 Coverage in 2026: Everything Seniors Need to Know

The Historical Problem: Medicare’s Weight-Loss Drug Exclusion

Since 2003, Medicare Part D has explicitly excluded coverage for medications prescribed for weight loss. This exclusion was written into the Medicare Modernization Act at a time when weight-loss drugs were largely appetite suppressants with modest efficacy and significant safety concerns.

The exclusion persisted even as GLP-1 medications transformed the obesity treatment landscape. Patients on Medicare could get Ozempic covered for diabetes but not Wegovy for weight loss — despite both containing the same active ingredient. This created a bizarre situation where physicians would sometimes prescribe Ozempic off-label for weight loss in diabetic patients, using the diabetes indication to access insurance coverage.

The Treat and Reduce Obesity Act, introduced multiple times in Congress, sought to end this exclusion but failed to pass. It took executive action and regulatory creativity to begin changing the landscape in 2026.

The Bridge Program: July–December 2026

The Trump Administration negotiated a Medicare GLP-1 Bridge Program that runs from July 1 through December 31, 2026. Key features:

Patient copay: Approximately $50 per month for eligible Medicare beneficiaries. This is a dramatic reduction from the $1,000+ monthly list price of brand-name GLP-1 medications.

Eligible medications: The specific medications covered under the Bridge Program will be determined by CMS. Expect Wegovy and potentially the Wegovy pill to be included, given Novo Nordisk’s cooperation with the pricing structure.

Eligibility criteria: Medicare Part D beneficiaries with a BMI qualifying for the medication’s FDA-approved indication. Prior authorization requirements are expected. Specific criteria will be published before the July 1 start date.

Duration: Six months. This is designed as a bridge to the more permanent BALANCE Model and IRA-negotiated pricing that begins in January 2027.

The BALANCE Model

BALANCE (Broadening Affordability and Leveraging Access for Necessary Care in Endocrinology) is a CMS innovation model that creates a structured framework for GLP-1 coverage in government insurance programs.

Medicaid phase (May 2026): The model first launches in Medicaid, providing states with a framework for covering GLP-1 medications for eligible populations. States can opt into the model, which includes negotiated pricing with manufacturers.

Medicare Part D phase (January 2027): The model expands to Medicare Part D, creating permanent coverage for GLP-1 medications for weight loss. This represents the end of the decades-long exclusion.

The BALANCE Model includes outcomes tracking requirements, meaning CMS will monitor whether patients are achieving clinical benefits from the medications. This data will inform future coverage decisions and may influence which specific medications remain on formulary.

IRA Price Negotiation: Ozempic at $274/Month Starting 2027

The Inflation Reduction Act (IRA) gave Medicare the power to negotiate prices for certain high-cost drugs. Ozempic was selected for negotiation, and the negotiated price of $274 per month takes effect January 1, 2027.

This is significant for several reasons. The current list price for Ozempic is approximately $900–$1,000/month. At $274/month, the negotiated Medicare price approaches the range of compounded semaglutide ($150–$400/month). For Medicare beneficiaries, this will make brand-name semaglutide financially accessible for the first time.

Important note: the IRA negotiated price applies specifically to Ozempic (for diabetes). Wegovy pricing under Medicare will be determined by the BALANCE Model and separate negotiations. However, the Ozempic price creates a benchmark that will influence Wegovy pricing discussions.

What This Means for Compounded GLP-1 Users on Medicare

If you’re a Medicare beneficiary currently using compounded semaglutide because Medicare wouldn’t cover the brand-name version, the landscape shifts dramatically in 2026–2027:

July 2026: The Bridge Program may offer brand-name GLP-1 access at $50/month — potentially cheaper than your current compounded program.

January 2027: Permanent Medicare Part D coverage through BALANCE, plus the IRA-negotiated Ozempic price of $274/month, creates sustainable long-term access to FDA-approved semaglutide.

The transition isn’t automatic. You’ll need to work with your prescriber to obtain a prescription for the brand-name product and navigate your Part D plan’s formulary and prior authorization process. But the financial barrier that drove many Medicare patients to compounding is being removed.

For patients who prefer compounded semaglutide (for custom dosing, added B12, or other personalization), it remains an option. But the cost advantage that made compounding essential for Medicare patients is shrinking.

What About Wegovy Specifically?

Novo Nordisk has announced plans to cut Wegovy’s list price to $675 in 2027. Combined with Medicare Part D coverage and the $2,000 annual out-of-pocket cap that takes effect under the IRA, the annual patient cost for Wegovy on Medicare could be substantially lower than the current out-of-pocket cost for compounded alternatives.

The Wegovy pill at $149–$299/month may also be included in the Bridge Program and BALANCE Model, potentially making it available to Medicare beneficiaries at even lower copays than the self-pay price.